About Cynosure (NASDAQ:CYNO)
Cynosure, Inc. develops, manufactures and markets aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, reduce fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus, ablate sweat glands and improve women's health. The Company also markets radiofrequency (RF), energy-sourced medical devices for surgical applications, such as facial plastic and general surgery, gynecology, ear, nose, and throat procedures, ophthalmology, oral and maxillofacial surgery, podiatry and proctology. The Company sells its products globally under the Cynosure, Palomar, ConBio and Ellman brand names. Its product portfolio includes single energy source systems, as well as workstations that incorporate two or more different types of lasers or light-based technologies.
Industry, Sector and Symbol:
- Sector: Healthcare
- Industry: Advanced Medical Equipment & Technology
- Sub-Industry: Health Care Equipment
- Symbol: NASDAQ:CYNO
- CUSIP: 23257720
- Web: www.cynosure.com/
Average Prices:- 50 Day Moving Avg: $62.47
- 200 Day Moving Avg: $50.89
- 52 Week Range: $39.90 - $66.65
P/E:- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: 32.50
- P/E Growth: 0.00
Profitability:- Net Margins: 0.70%
- Return on Equity: 0.75%
- Return on Assets: 0.59%
Debt:- Debt-to-Equity Ratio: 0.04%
- Current Ratio: 3.28%
- Quick Ratio: 2.54%
Misc:- Average Volume: 1.17 million shs.
- Beta: 1.65
Frequently Asked Questions for Cynosure (NASDAQ:CYNO)
What is Cynosure's stock symbol?
Cynosure trades on the NASDAQ under the ticker symbol "CYNO."
How were Cynosure's earnings last quarter?
Cynosure, Inc. (NASDAQ:CYNO) released its earnings results on Tuesday, July, 26th. The company reported $0.36 earnings per share for the quarter, topping the Zacks' consensus estimate of $0.29 by $0.07. The business had revenue of $110.30 million for the quarter, compared to analyst estimates of $101.31 million. Cynosure had a net margin of 0.70% and a return on equity of 0.75%. The business's revenue was up 31.8% on a year-over-year basis. During the same period last year, the company posted $0.30 EPS. View Cynosure's Earnings History.
Where is Cynosure's stock going? Where will Cynosure's stock price be in 2017?
7 analysts have issued 12-month price targets for Cynosure's shares. Their predictions range from $40.00 to $66.00. On average, they expect Cynosure's stock price to reach $58.33 in the next twelve months. View Analyst Ratings for Cynosure.
Who are some of Cynosure's key competitors?
Some companies that are related to Cynosure include Thermo Fisher Scientific (TMO), Danaher Corporation (DHR), Intuitive Surgical (ISRG), Boston Scientific Corporation (BSX), Koninklijke Philips N.V. (PHG), Illumina (ILMN), Edwards Lifesciences Corporation (EW), Cerner Corporation (CERN), Agilent Technologies (A), Waters Corporation (WAT), ResMed (RMD), Hologic (HOLX), Varian Medical Systems (VAR), PerkinElmer (PKI), ABIOMED (ABMD), Bruker Corporation (BRKR), Alere (ALR) and Quidel Corporation (QDEL).
How do I buy Cynosure stock?
Shares of Cynosure can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cynosure's stock price today?
One share of Cynosure stock can currently be purchased for approximately $65.97.
MarketBeat Community Rating for Cynosure (NASDAQ CYNO)MarketBeat's community ratings are surveys of what our community members think about Cynosure and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.
Consensus Ratings for Cynosure (NASDAQ:CYNO) (How are Consensus Ratings Calculated?) MarketBeat calculates consensus ratings using the most recent rating from each brokerage that has rated a stock within the last twelve months. Since brokers often use different ratings systems, each rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings. Each stock's consensus rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months.
MarketBeat will no longer include ratings and price target data in its consensus calculation if a broker drops coverage and MarketBeat has received a report that coverage was dropped. Ratings from certain research firms that issue ratings using purely quantitative methods (such as Zacks, Vetr and ValuEngine) are not included in consensus calculations. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
| Ratings Breakdown: | 3 Hold Ratings, 4 Buy Ratings |
| Consensus Rating: | Buy (Score: 2.57) |
| Consensus Price Target: | $58.33 (11.58% downside) |
Consensus Price Target History for Cynosure (NASDAQ:CYNO)
Analysts' Ratings History for Cynosure (NASDAQ:CYNO)
Show:
| Date | Firm | Action | Rating | Price Target | Impact on Share Price | Details |
|---|
| 3/28/2017 | Aegis | Reiterated Rating | Hold | $66.00 | N/A |  |
| 2/16/2017 | Northland Securities | Reiterated Rating | Outperform | $60.00 | N/A | |
| 2/14/2017 | Northcoast Research | Upgrade | Sell -> Neutral | | N/A | |
| 2/14/2017 | Maxim Group | Downgrade | Buy -> Hold | $66.00 | N/A | |
| 10/28/2016 | Leerink Swann | Reiterated Rating | Outperform | $63.00 -> $60.00 | N/A | |
| 10/26/2016 | Stifel Nicolaus | Reiterated Rating | Buy | $62.00 -> $58.00 | N/A | |
| 10/24/2016 | Brean Capital | Reiterated Rating | Buy | | N/A | |
(Data available from 10/23/2015 forward)
Earnings History for Cynosure (NASDAQ:CYNO)Earnings History by Quarter for Cynosure (NASDAQ CYNO)| Date | Quarter | Consensus Estimate | Actual EPS | Revenue Estimate | Actual Revenue | Release Link | Conference Call | Details |
|---|
| 2/7/2017 | Q416 | $0.41 | $0.44 | $119.97 million | $122.10 million | View | Listen | |
| 10/25/2016 | Q316 | $0.28 | $0.29 | $101.11 million | $106.40 million | View | Listen | |
| 7/26/2016 | Q216 | $0.29 | $0.36 | $101.31 million | $110.30 million | View | Listen | |
| 4/26/2016 | Q116 | $0.14 | $0.19 | $85.78 million | $94.70 million | View | Listen | |
| 2/9/2016 | Q415 | $0.36 | $0.42 | $95.01 million | $102.40 million | View | Listen | |
| 10/27/2015 | Q315 | $0.18 | $0.21 | $76.68 million | $78.40 million | View | Listen | |
| 7/28/2015 | Q215 | $0.27 | $0.30 | $82.71 million | $83.70 million | View | Listen | |
| 5/5/2015 | Q1 | $0.17 | $0.15 | $70.87 million | $74.90 million | View | Listen | |
| 2/10/2015 | Q414 | $0.39 | $0.36 | $83.01 million | $86.30 million | View | Listen | |
| 10/28/2014 | Q314 | $0.24 | $0.25 | $69.94 million | $71.50 million | View | Listen | |
| 7/29/2014 | Q214 | $0.30 | $0.32 | $71.15 million | $72.60 million | View | Listen | |
| 5/6/2014 | Q1 | $0.23 | $0.19 | $64.70 million | $62.00 million | View | Listen | |
| 2/12/2014 | Q413 | $0.19 | $0.39 | $67.80 million | $74.50 million | View | Listen | |
| 10/29/2013 | Q313 | $0.19 | $0.23 | $61.60 million | $60.70 million | View | Listen | |
| 7/31/2013 | Q2 2013 | $0.20 | $0.29 | $46.96 million | $50.09 million | View | Listen | |
| 4/30/2013 | Q1 2013 | $0.13 | $0.12 | $38.51 million | $10.70 million | View | Listen | |
| 2/12/2013 | Q4 2012 | $0.23 | $0.27 | $40.98 million | $47.70 million | View | Listen | |
| 10/23/2012 | | $0.12 | $0.25 | | | View | N/A | |
| 7/24/2012 | | $0.12 | $0.20 | | | View | N/A | |
| 5/1/2012 | | ($0.02) | $0.06 | | | View | N/A | |
| 2/14/2012 | | $0.05 | $0.08 | | | View | N/A | |
| 10/25/2011 | | $0.04 | ($0.06) | | | View | N/A | |
| 5/3/2011 | | ($0.05) | ($0.15) | | | View | N/A | |
| 2/15/2011 | | ($0.03) | ($0.06) | | | View | N/A | |
(Data available from 1/1/2011 forward)
Earnings Estimates for Cynosure (NASDAQ:CYNO)2017 EPS Consensus Estimate: $1.63
2018 EPS Consensus Estimate: $2.02
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|
| Q1 2017 | 3 | $0.23 | $0.26 | $0.24 |
| Q2 2017 | 3 | $0.40 | $0.44 | $0.43 |
| Q3 2017 | 3 | $0.38 | $0.42 | $0.40 |
| Q4 2017 | 3 | $0.51 | $0.61 | $0.57 |
| Q1 2018 | 1 | $0.34 | $0.34 | $0.34 |
| Q2 2018 | 1 | $0.51 | $0.51 | $0.51 |
| Q3 2018 | 1 | $0.50 | $0.50 | $0.50 |
| Q4 2018 | 1 | $0.67 | $0.67 | $0.67 |
(Data provided by Zacks Investment Research)
Dividend History for Cynosure (NASDAQ:CYNO)
No dividend announcements for this company have been tracked by MarketBeat.com
Insider Trading and Institutional Ownership History for Cynosure (NASDAQ:CYNO)Insider Ownership Percentage: 2.90%
Insider Trades by Quarter for Cynosure (NASDAQ:CYNO)| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Details |
|---|
| 11/22/2016 | Douglas J Delaney | VP | Sell | 7,875 | $45.00 | $354,375.00 | |
| 11/22/2016 | Michael R Davin | Chairman | Sell | 16,284 | $45.00 | $732,780.00 | |
| 8/30/2016 | Brian M Barefoot | Director | Sell | 21,000 | $51.66 | $1,084,860.00 | |
| 8/15/2016 | Michael R Davin | Chairman | Sell | 12,062 | $53.35 | $643,507.70 | |
| 8/15/2016 | Timothy W Baker | CFO | Sell | 5,834 | $53.35 | $311,243.90 | |
| 8/11/2016 | Michael R Davin | Chairman | Sell | 4,222 | $53.18 | $224,525.96 | |
| 8/11/2016 | Timothy W Baker | CFO | Sell | 2,041 | $53.19 | $108,560.79 | |
| 5/13/2016 | Douglas J Delaney | VP | Sell | 12,299 | $46.60 | $573,133.40 | |
| 5/13/2016 | Michael R Davin | CEO | Sell | 26,271 | $46.59 | $1,223,965.89 | |
| 5/13/2016 | Timothy W Baker | CFO | Sell | 12,451 | $46.60 | $580,216.60 | |
| 4/18/2016 | Douglas J Delaney | VP | Sell | 15,890 | $45.01 | $715,208.90 | |
| 4/18/2016 | Michael R Davin | CEO | Sell | 74,729 | $45.31 | $3,385,970.99 | |
| 4/18/2016 | Timothy W Baker | CFO | Sell | 14,008 | $45.02 | $630,640.16 | |
| 4/14/2016 | Douglas J Delaney | VP | Sell | 24,488 | $45.02 | $1,102,449.76 | |
| 4/14/2016 | Michael R Davin | CEO | Sell | 61,377 | $45.01 | $2,762,578.77 | |
| 4/14/2016 | Timothy W Baker | CFO | Sell | 39,857 | $45.02 | $1,794,362.14 | |
| 4/13/2016 | Michael R Davin | CEO | Sell | 72 | $45.00 | $3,240.00 | |
| 4/6/2016 | Douglas J Delaney | VP | Sell | 4,408 | $45.08 | $198,712.64 | |
| 4/6/2016 | Michael R Davin | CEO | Sell | 4,869 | $45.11 | $219,640.59 | |
| 4/6/2016 | Timothy W Baker | CFO | Sell | 4,413 | $45.08 | $198,938.04 | |
| 4/4/2016 | Douglas J Delaney | VP | Sell | 66,626 | $45.47 | $3,029,484.22 | |
| 4/4/2016 | Michael R Davin | CEO | Sell | 66,259 | $45.61 | $3,022,072.99 | |
| 4/4/2016 | Timothy W Baker | CFO | Sell | 53,297 | $45.60 | $2,430,343.20 | |
| 12/31/2015 | Michael R. Davin | CEO | Sell | 200 | $45.00 | $9,000.00 | |
| 12/31/2015 | Timothy W. Baker | CFO | Sell | 100 | $45.00 | $4,500.00 | |
| 6/1/2015 | Ettore V Biagioni | Director | Sell | 24,000 | $36.25 | $870,000.00 | |
| 5/20/2015 | Douglas J Delaney | VP | Sell | 89,000 | $38.01 | $3,382,890.00 | |
| 5/20/2015 | Michael R Davin | CEO | Sell | 151,000 | $38.07 | $5,748,570.00 | |
| 4/23/2015 | Michael R Davin | CEO | Sell | 6,991 | $33.04 | $230,982.64 | |
| 4/10/2015 | Michael R Davin | CEO | Sell | 44,677 | $33.01 | $1,474,787.77 | |
| 4/9/2015 | Douglas J Delaney | VP | Sell | 28,335 | $33.01 | $935,338.35 | |
| 4/9/2015 | Michael R Davin | CEO | Sell | 70,000 | $32.00 | $2,240,000.00 | |
| 4/8/2015 | Douglas J Delaney | VP | Sell | 45,000 | $32.00 | $1,440,000.00 | |
| 1/9/2015 | Ettore V Biagioni | Director | Sell | 12,000 | $30.09 | $361,080.00 | |
| 12/2/2014 | Ettore V Biagioni | Director | Sell | 2,500 | $28.00 | $70,000.00 | |
| 11/24/2014 | Ettore V Biagioni | Director | Sell | 5,000 | $27.28 | $136,400.00 | |
| 11/5/2013 | Marina Hatsopoulos | Director | Buy | 3,000 | $22.60 | $67,800.00 | |
| 9/5/2012 | Douglas J Delaney | VP | Sell | 16,904 | $27.65 | $467,395.60 | |
| 9/5/2012 | Michael R Davin | CEO | Sell | 16,770 | $27.65 | $463,690.50 | |
| 9/5/2012 | Timothy W Baker | CFO | Sell | 16,854 | $27.65 | $466,013.10 | |
(Data available from 1/1/2013 forward)
Headline Trends for Cynosure (NASDAQ:CYNO)
Latest Headlines for Cynosure (NASDAQ:CYNO)
| Source: |
|
Loading headlines, please wait.
Cynosure (CYNO) Chart for Monday, October, 23, 2017
